COVID-19 与 CAR T 细胞：EHA-IDWP 的 EPICOVIDEHA 调查对当前挑战和未来方向的报告。
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
机构信息
Stem Cell Transplant Center, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.
Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
出版信息
Blood Adv. 2022 Apr 12;6(7):2427-2433. doi: 10.1182/bloodadvances.2021005616.
Abstract
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
摘要
EHA-IDWP 开发了一个观察性登记处，收集接受 CAR T 细胞治疗的患者 COVID-19 感染的数据。COVID-19 的患病率为 4.8%，总死亡率为 50%，这突出表明需要预防这些患者感染。
相似文献
1
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.COVID-19 与 CAR T 细胞：EHA-IDWP 的 EPICOVIDEHA 调查对当前挑战和未来方向的报告。
Blood Adv. 2022 Apr 12;6(7):2427-2433. doi: 10.1182/bloodadvances.2021005616.
2
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.随着时间的推移，接受 CAR T 细胞治疗的 COVID-19 患者的预后得到改善：代表欧洲血液和骨髓移植学会（EBMT）传染病工作组（IDWP）和欧洲血液学协会（EHA）淋巴瘤小组进行的欧洲 COVID-19 多中心研究的更新。
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
3
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.制造用于过继性免疫治疗的嵌合抗原受体（CAR）T细胞。
J Vis Exp. 2019 Dec 17(154). doi: 10.3791/59949.
4
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.嵌合抗原受体 (CAR)-T 细胞免疫疗法治疗胸部恶性肿瘤：挑战与机遇。
Front Immunol. 2022 Jul 14;13:871661. doi: 10.3389/fimmu.2022.871661. eCollection 2022.
5
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.嵌合抗原受体 T 细胞治疗霍奇金淋巴瘤和 T 细胞淋巴瘤。
Hematol Oncol Clin North Am. 2023 Dec;37(6):1107-1124. doi: 10.1016/j.hoc.2023.05.017. Epub 2023 Jun 23.
6
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造：创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
7
CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through.嵌合抗原受体 T 细胞用于癌症免疫治疗——前路漫漫，行则将至。
Int Rev Immunol. 2022;41(6):567-581. doi: 10.1080/08830185.2022.2080820. Epub 2022 May 28.
8
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.过继细胞疗法治疗实体瘤：当前的挑战与新兴治疗进展。
J Control Release. 2024 Apr;368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.
9
Engineering enhanced CAR T-cells for improved cancer therapy.工程改造增强型嵌合抗原受体T细胞以改善癌症治疗。
Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.
10
Advances and Challenges of CAR T Cells in Clinical Trials.嵌合抗原受体T细胞在临床试验中的进展与挑战
Recent Results Cancer Res. 2020;214:93-128. doi: 10.1007/978-3-030-23765-3_3.
引用本文的文献
1
Meta-analysis of mortality factors after COVID-19 infection in pediatric oncology patients.儿童肿瘤患者新冠病毒感染后死亡因素的荟萃分析
Front Oncol. 2025 Aug 6;15:1594617. doi: 10.3389/fonc.2025.1594617. eCollection 2025.
2
Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.基于片段的免疫细胞衔接抗体在癌症、感染性疾病和自身免疫性疾病治疗中的应用：临床和转化研究的经验与见解
Antibodies (Basel). 2025 Jun 24;14(3):52. doi: 10.3390/antib14030052.
3
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染不影响接受嵌合抗原受体（CAR）T细胞疗法治疗的复发/难治性大B细胞淋巴瘤患者的治疗结果。
Ann Hematol. 2025 Jun 4. doi: 10.1007/s00277-025-06425-8.
4
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.免疫功能低下患者接种新型冠状病毒肺炎疫苗的免疫原性（Auto-COVID-VACC）：多中心前瞻性非干预性研究方案
JMIR Res Protoc. 2025 May 26;14:e60675. doi: 10.2196/60675.
5
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.四类免疫功能低下人群中发生重症新型冠状病毒肺炎的风险：法国专家观点
Infect Dis Ther. 2025 Apr;14(4):671-733. doi: 10.1007/s40121-025-01124-3. Epub 2025 Mar 18.
6
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.嵌合抗原受体T细胞疗法治疗侵袭性B细胞非霍奇金淋巴瘤患者后的晚期不良事件
JAMA Netw Open. 2025 Feb 3;8(2):e2461683. doi: 10.1001/jamanetworkopen.2024.61683.
7
Chimeric antigen receptor T-cell therapy in autoimmune diseases.嵌合抗原受体T细胞疗法在自身免疫性疾病中的应用
Front Immunol. 2024 Nov 19;15:1492552. doi: 10.3389/fimmu.2024.1492552. eCollection 2024.
8
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.曲折之路：COVID-19 时代 CAR-T 及其他新型过继性细胞疗法的传染病考量
Semin Hematol. 2024 Oct;61(5):321-332. doi: 10.1053/j.seminhematol.2024.08.002. Epub 2024 Aug 23.
9
Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections.嵌合抗原受体-T 细胞疗法的病毒问题：潜伏性和偶发性病毒感染。
Curr Opin Infect Dis. 2024 Dec 1;37(6):526-535. doi: 10.1097/QCO.0000000000001066. Epub 2024 Oct 3.
10
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.随着时间的推移，接受 CAR T 细胞治疗的 COVID-19 患者的预后得到改善：代表欧洲血液和骨髓移植学会（EBMT）传染病工作组（IDWP）和欧洲血液学协会（EHA）淋巴瘤小组进行的欧洲 COVID-19 多中心研究的更新。
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
本文引用的文献
1
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19.EPICOVIDEHA：一个用于COVID-19血液病患者流行病学研究的即用型平台。
Hemasphere. 2021 Jun 25;5(7):e612. doi: 10.1097/HS9.0000000000000612. eCollection 2021 Jul.
2
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.COVID-19 与干细胞移植：来自 EBMT 和 GETH 多中心前瞻性调查的结果。
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
3
CAR-T cell therapy: current limitations and potential strategies.嵌合抗原受体 T 细胞疗法：当前的局限性和潜在策略。
Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7.
4
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
5
Immunologic characterization of COVID-19 patients with hematological cancer.血液恶性肿瘤 COVID-19 患者的免疫学特征。
Haematologica. 2020 Dec 17;106(5):1457-1460. doi: 10.3324/haematol.2020.269878.
6
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
7
COVID-19 in hematopoietic cell transplant recipients.造血干细胞移植受者中的 COVID-19。
Bone Marrow Transplant. 2021 Apr;56(4):952-955. doi: 10.1038/s41409-020-01084-x. Epub 2020 Oct 28.
8
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.造血干细胞移植受者 COVID-19 的良好结局。
J Clin Invest. 2020 Dec 1;130(12):6656-6667. doi: 10.1172/JCI141777.
9
Risk factors and outcome of COVID-19 in patients with hematological malignancies.血液系统恶性肿瘤患者感染新型冠状病毒肺炎的危险因素及预后
Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020.
10
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.意大利血液系统恶性肿瘤患者中与COVID-19严重程度相关的临床特征和危险因素：一项回顾性、多中心队列研究。
Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
Zotero 插件